Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441000 (BNT131) +/- Cemiplimab in Advanced Solid Tumors
NCT03871348Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, mRNA Therapeutics
- Countries
- 6
01
Overview
Phase 1, open-label trial of SAR441000 in solid tumor, melanoma, cutaneous squamous cell carcinoma (cSCC) and 1 more (6 arms), sponsored by Sanofi. Primary endpoints: Incidence of Dose Limiting Toxicities at Cycle 1, Maximum Tolerated Dose and 2 more. Started Jan 2019; status: terminated.
02
Drugs
SAR441000
03
Conditions
solid tumormelanomacutaneous squamous cell carcinoma (cSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03871348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871348.